The Royal Marsden and its academic partner The Institute of Cancer Research (ICR) work as one integrated organisation to rapidly move science from bench to bedside. Our joint bench-to-bedside ethos means that clinical research and drug trials are central to our work as one of Europe’s largest comprehensive cancer centres.
Together, The Royal Marsden and the ICR also make up the only National Institute for Health Research Biomedical Research Centre dedicated to cancer in the UK.
This unique relationship provides a privileged framework from which to apply knowledge about the basic science of cancer to translational research and clinical practice. This leads to:
- an improved understanding of the molecular development of cancer
- advancement in the identification of new drug targets
- better outcomes through personalised treatment for patients with cancer.
The partnership helps to pioneer new cancer therapies through complex translational studies and phase I/II clinical trials. We recruit more patients onto these trials than any other similar sized hospital in the UK.
With more than 450 clinical trials taking place at The Royal Marsden each year, our research work is internationally renowned and influences how cancer patients are treated and cared for around the world.